CL2007003711A1 - Composicion farmaceutica liquida transdermica que comprende un primer y segundo mejorador de la penetracion dermica, un solvente primario aprotico y una cantidad efectiva de flunixina o una sal farmaceuticamente aceptable de la misma; y uso para el t - Google Patents

Composicion farmaceutica liquida transdermica que comprende un primer y segundo mejorador de la penetracion dermica, un solvente primario aprotico y una cantidad efectiva de flunixina o una sal farmaceuticamente aceptable de la misma; y uso para el t

Info

Publication number
CL2007003711A1
CL2007003711A1 CL2007003711A CL2007003711A CL2007003711A1 CL 2007003711 A1 CL2007003711 A1 CL 2007003711A1 CL 2007003711 A CL2007003711 A CL 2007003711A CL 2007003711 A CL2007003711 A CL 2007003711A CL 2007003711 A1 CL2007003711 A1 CL 2007003711A1
Authority
CL
Chile
Prior art keywords
dermic
flunixin
penetration
improvement
pharmaceutically acceptable
Prior art date
Application number
CL2007003711A
Other languages
English (en)
Spanish (es)
Inventor
Cheyney Freehauf Keith Meadows
Original Assignee
Schering Plough Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Ltd filed Critical Schering Plough Ltd
Publication of CL2007003711A1 publication Critical patent/CL2007003711A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2007003711A 2006-12-20 2007-12-19 Composicion farmaceutica liquida transdermica que comprende un primer y segundo mejorador de la penetracion dermica, un solvente primario aprotico y una cantidad efectiva de flunixina o una sal farmaceuticamente aceptable de la misma; y uso para el t CL2007003711A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87090706P 2006-12-20 2006-12-20

Publications (1)

Publication Number Publication Date
CL2007003711A1 true CL2007003711A1 (es) 2008-07-25

Family

ID=39262615

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007003711A CL2007003711A1 (es) 2006-12-20 2007-12-19 Composicion farmaceutica liquida transdermica que comprende un primer y segundo mejorador de la penetracion dermica, un solvente primario aprotico y una cantidad efectiva de flunixina o una sal farmaceuticamente aceptable de la misma; y uso para el t

Country Status (19)

Country Link
US (1) US9006272B2 (enExample)
EP (1) EP2120860B1 (enExample)
JP (1) JP5377326B2 (enExample)
KR (1) KR20090091328A (enExample)
CN (2) CN101588789B (enExample)
AR (1) AR064425A1 (enExample)
AU (1) AU2007339312B2 (enExample)
BR (1) BRPI0720500B1 (enExample)
CA (1) CA2672964C (enExample)
CL (1) CL2007003711A1 (enExample)
CO (1) CO6190598A2 (enExample)
ES (1) ES2714550T3 (enExample)
MX (1) MX2009006893A (enExample)
NZ (1) NZ598554A (enExample)
PE (1) PE20081406A1 (enExample)
RU (1) RU2466715C2 (enExample)
TW (1) TWI350182B (enExample)
WO (1) WO2008082507A2 (enExample)
ZA (1) ZA200904329B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2738970A1 (en) * 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
CA2828086C (en) 2010-03-10 2018-07-31 Nuvo Research Inc. Foamable formulation
WO2012022837A1 (en) * 2010-08-16 2012-02-23 Helsingin Yliopisto Transdermal compositions
WO2012043701A1 (ja) * 2010-09-30 2012-04-05 富山化学工業株式会社 経皮吸収製剤
CN114903848A (zh) * 2013-02-27 2022-08-16 阿根塔创新有限公司 透皮制剂
CN105769827B (zh) * 2016-03-09 2018-07-17 金陵科技学院 用于动物清热镇痛氟尼辛葡甲胺涂膜剂及其制备方法
KR20200065711A (ko) 2018-11-30 2020-06-09 한원경 동물 피부질환 개선용 조성물
WO2021010843A1 (en) 2019-07-16 2021-01-21 Donaghys Limited Transdermal solvent system and methods of use
WO2021045870A1 (en) * 2019-09-06 2021-03-11 Iowa State University Research Foundation, Inc. Mirtazapine as a pre-shipping inhibitor of bovine respiratory disease
JP7846689B2 (ja) * 2020-11-25 2026-04-15 インターベット インターナショナル ベー． フェー． フルニキシンを口腔投与することによる疼痛の治療方法
WO2022238965A1 (en) * 2021-05-12 2022-11-17 Argenta Innovation Limited Veterinary transdermal formulation
CN114404360B (zh) * 2021-12-16 2023-03-28 江西益昕葆生物科技有限公司 一种氟尼辛葡甲胺注射液的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63225316A (ja) * 1986-10-21 1988-09-20 Nitto Electric Ind Co Ltd 外皮投与用組成物
JPH11222443A (ja) * 1997-11-11 1999-08-17 Saitama Daiichi Seiyaku Kk 経皮吸収促進組成物および経皮吸収製剤
AU1780101A (en) 1999-11-19 2001-05-30 Xel Herbaceuticals Transdermal delivery system for alkaloids of aconitum species
JP4865958B2 (ja) * 2001-05-23 2012-02-01 株式会社トクホン 鎮痛抗炎症局所作用型の貼付剤
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
CA2530407A1 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
JP2007500691A (ja) 2003-07-31 2007-01-18 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 抗炎症剤の分散性製剤
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
US7618651B2 (en) * 2004-06-24 2009-11-17 Idexx Laboratories Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
CA2573412A1 (en) * 2004-07-19 2006-02-02 Warner-Lambert Company Llc Formulation for stimulating hair growth
AU2005284422A1 (en) * 2004-09-16 2006-03-23 Bayer Healthcare Ag Dermally applicable formulations for treating skin diseases in animals
WO2007061739A2 (en) * 2005-11-21 2007-05-31 Schering-Plough Ltd. Pharmaceutical compositions comprising buprenorphine

Also Published As

Publication number Publication date
TW200833367A (en) 2008-08-16
AU2007339312A1 (en) 2008-07-10
CA2672964A1 (en) 2008-07-10
RU2009127500A (ru) 2011-01-27
CA2672964C (en) 2018-04-03
KR20090091328A (ko) 2009-08-27
CO6190598A2 (es) 2010-08-19
RU2466715C2 (ru) 2012-11-20
CN103690471B (zh) 2015-11-18
NZ598554A (en) 2013-08-30
EP2120860A2 (en) 2009-11-25
WO2008082507A3 (en) 2009-03-19
US20080153885A1 (en) 2008-06-26
TWI350182B (en) 2011-10-11
JP2010513500A (ja) 2010-04-30
BRPI0720500A8 (pt) 2015-12-29
MX2009006893A (es) 2009-07-03
ZA200904329B (en) 2010-05-26
ES2714550T3 (es) 2019-05-29
BRPI0720500B1 (pt) 2019-01-02
CN103690471A (zh) 2014-04-02
US9006272B2 (en) 2015-04-14
AU2007339312B2 (en) 2013-06-06
WO2008082507A2 (en) 2008-07-10
JP5377326B2 (ja) 2013-12-25
CN101588789A (zh) 2009-11-25
AR064425A1 (es) 2009-04-01
BRPI0720500A2 (pt) 2014-02-04
CN101588789B (zh) 2013-12-11
PE20081406A1 (es) 2008-10-17
EP2120860B1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
CL2004000698A1 (es) Comosicion farmaceutica no acuosa que comprende al menos un ingrediente activo y un vehiculo de fase unica que contiene al menos un polimero y al menos un solvente, siendo el vehiculo miscible en agua; procedimiento para su preparacion; dispositivo d
BRPI0809667A2 (pt) Composto, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2007001902A1 (es) Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.
CL2007003552A1 (es) Compuestos derivados de pirimidina y piridina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno proliferativo celular.
CL2007001870A1 (es) Composicion farmaceutica de dosificacion solida que comprende valsartan, amlodipina, hidroclorotiazida y aditivos farmaceuticamente aceptables; procedimiento de preparacion; y uso para el tratamiento de hipertension, insuficiencia cardiaca, infarto d
AR061348A1 (es) Preparados estables de laquinimod
BRPI0922364A2 (pt) Composto, composição farmacêutica e uso de um composto
BR112012012446A2 (pt) "concentrado alimentar temperado, processo, uso, composição alimentar pronta para consumo e usp de um poliol líquido"
CL2007003302A1 (es) Sistema integrado de almacenamiento y entrega para composiciones nutricionales, que comprende un sello penetrable, una tapa y una punta con proyeccion la que se mueve entre los dos costados de dicho sello; metodo de uso de dicho sistema; kit que comp
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
BRPI0810390A2 (pt) Película, composição, e, métodos para administrar um material ativo, para melhorar a estabilidade de uma película e para manter a saúde sistêmica de um mamífero
CL2007002526A1 (es) Un medicamento que comprende, separado o juntos: a) una sal de glicopirronio; b) un agonista del adreno-receptor beta-2 seleccionado de salmeterol y formoterol; y c) un corticosteroide; kit farmaceutico; y uso en el tratamiento de una enfermedad infl
BRPI0811180A2 (pt) Uso de probióticos ou uma mistura dos mesmos para a preparação de composição farmacêutica utilizável em um ambiente pré e/ou pós-cirúrgico.
WO2008008364A3 (en) Enhanced stability phenylephrine liquid compositions
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CL2007003154A1 (es) Compuestos derivados de pirazolina; composicion farmaceutica que comprende a los compuestos; y uso para tratar afecciones cardiovasculares, renales, hepaticas y vasculares entre otras.
CL2013000098A1 (es) Composicion farmaceutica que contienen una formulacion activada y potenciada de un anticuerpo para el receptor canabinoide humano; metodos de uso.
CL2007003722A1 (es) Compuestos derivados de propionamida n-sustituida por heterociclo, activadores de glucoquinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento o prevencion de la diabetes.
BRPI0908208A2 (pt) Composto derivado de oxazolidinona, medicamento, composição farmacêutica que o contém e uso desse composto.
UY30736A1 (es) Compuestos quimicos 537
BRPI0916571A2 (pt) composto derivado de alquilaminometiloxazolidinona tricíclo, medicamento e composição farmacêutica que o contém e uso do composto
BRPI0720546A2 (pt) Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto